ABIONYX Pharma Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-5.5	-4.38	-3.52	-4.21	-5.82	Upgrade
Depreciation & Amortization	-	0.5	0.14	0.12	0.12	Upgrade
Other Amortization	-	0.01	0.01	0.01	0	Upgrade
Stock-Based Compensation	-	0.63	0.02	0.51	0.82	Upgrade
Other Operating Activities	2.6	-0.36	-0.89	0.11	-0.06	Upgrade
Change in Accounts Receivable	-	-0.08	0.38	0.04	-0.1	Upgrade
Change in Inventory	-	0.04	-0.08	0.03	0.01	Upgrade
Change in Other Net Operating Assets	-	0.02	0.23	0.03	-1.66	Upgrade
Operating Cash Flow	-2.9	-3.63	-3.7	-3.36	-6.69	Upgrade
Capital Expenditures	-	-0.07	-0.1	-0.17	-0.17	Upgrade
Sale of Property, Plant & Equipment	-	-	-	-	0	Upgrade
Divestitures	-	-	-	-	1.5	Upgrade
Sale (Purchase) of Intangibles	-	-0.01	-0.03	-0.01	-	Upgrade
Other Investing Activities	-0.2	-	-	-	-	Upgrade
Investing Cash Flow	-0.2	-0.08	-0.13	-0.18	1.34	Upgrade
Long-Term Debt Repaid	-	-0.49	-0.3	-0.24	-0.02	Upgrade
Net Debt Issued (Repaid)	-	-0.49	-0.3	-0.24	-0.02	Upgrade
Issuance of Common Stock	-	3.36	4.19	0.04	4.06	Upgrade
Repurchase of Common Stock	-	-0.02	-	-	-	Upgrade
Other Financing Activities	3.4	-	-	-	-0.07	Upgrade
Financing Cash Flow	3.4	2.84	3.89	-0.19	3.97	Upgrade
Miscellaneous Cash Flow Adjustments	-	-0	-	-	-	Upgrade
Net Cash Flow	0.3	-0.87	0.06	-3.73	-1.38	Upgrade
Free Cash Flow	-2.9	-3.7	-3.8	-3.52	-6.86	Upgrade
Free Cash Flow Margin	-70.73%	-81.34%	-81.94%	-67.10%	-1016.00%	Upgrade
Free Cash Flow Per Share	-	-0.11	-0.13	-0.13	-0.28	Upgrade
Levered Free Cash Flow	-	-1.85	-2.47	-2.06	-5.04	Upgrade
Unlevered Free Cash Flow	-	-1.82	-2.46	-2.02	-5.03	Upgrade
Change in Working Capital	-	-0.03	0.54	0.1	-1.74	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.